stay updated

Khondrion appoints Tom Pulles, MD, as Chief Medical Officer

NIJMEGEN, the Netherlands – 1 June 2022: Khondrion (or the “Company”), a clinical stage biopharmaceutical company discovering and developing...

Khondrion completes enrollment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders

NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting...

Khondrion announces first patients dosed in KHENEREXT Phase IIb extension study examining long-term safety and efficacy of oral sonlicromanol in mitochondrial disease patients

Enabling continued treatment in 52-week multi-centre study for patients who have completed ongoing KHENERGYZE Phase IIb study investigating...

Khondrion to participate in Mitocon’s 11th Italian Meeting on Mitochondrial Diseases

NIJMEGEN, the Netherlands – 14 October 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...

Khondrion moves headquarters to Novio Tech Campus to support growth

NIJMEGEN, the Netherlands – 26 August 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...

Khondrion announces publication in PLOS ONE of new research showing normalisation of prostate cancer stem cell mPGES-1 overexpression and inhibition of cancer spheroid growth by sonlicromanol’s active metabolite

Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces the...

Patient Perspective: A conversation with Elja van der Veer – Former IMP Chair

A coffee with the Scientific Advisory Board: Prof. Dr. Michelangelo Mancuso

How did you cross paths with Khondrion? I heard about Khondrion from International Mito-Patients, the global network of patient organisations, and...

Patient Perspective: A conversation with Sam’s mother

When did Sam first start experiencing symptoms and how long did it take for him to be diagnosed? Sam was first diagnosed with mitochondrial disease...

A coffee with the Scientific Advisory Board: Prof. Dr. Marni Falk

How did you cross paths with Khondrion? I have crossed paths with Jan Smeitink, Khondrion’s CEO and Founder, multiple times at various international...

Patient Perspective: A conversation with Paulien

When did you first start experiencing mitochondrial disease symptoms and how long did it take to get your diagnosis? I had a very happy and...

A coffee with the Scientific Advisory Board: Sir Prof. Dr. Emeritus Doug Turnbull, Chairman

How did you cross paths with Khondrion? I heard about Khondrion from international colleagues and was made aware that this company was focused on...